Impact of performance status on treatment outcomes: A real-world study of advanced urothelial cancer treated with checkpoint inhibitors

Multi-institution retrospective cohort study showed that patients with ECOG PS ≥2 (compared to ECOG PS 0–1) had comparable overall response rate but worse overall survival with treatment with immune checkpoint inhibitor as first line therapy, while treatment initiation in the last 30 days of life wa...

Full description

Saved in:
Bibliographic Details
Published in:Cancer 2020-03, Vol.126 (6), p.1208-1216
Main Authors: Khaki, Ali Raza, Li, Ang, Diamantopoulos, Leonidas N, Bilen, Mehmet A., Santos, Victor, Esther, John, Morales-Barrera, Rafael, Devitt, Michael, Nelson, Ariel, Hoimes, Christopher J, Shreck, Evan, Assi, Hussein, Gartrell, Benjamin A, Sankin, Alex, Rodriguez-Vida, Alejo, Lythgoe, Mark, Pinato, David J., Drakaki, Alexandra, Joshi, Monika, Velho, Pedro Isaacsson, Hahn, Noah, Liu, Sandy, Buznego, Lucia Alonso, Duran, Ignacio, Moses, Marcus, Jain, Jayanshu, Murgic, Jure, Baratam, Praneeth, Barata, Pedro, Tripathi, Abhishek, Zakharia, Yousef, Galsky, Matthew D., Sonpavde, Guru, Yu, Evan Y, Shankaran, Veena, Lyman, Gary H, Grivas, Petros
Format: Article
Language:English
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Multi-institution retrospective cohort study showed that patients with ECOG PS ≥2 (compared to ECOG PS 0–1) had comparable overall response rate but worse overall survival with treatment with immune checkpoint inhibitor as first line therapy, while treatment initiation in the last 30 days of life was associated with increased odds of hospital death.
ISSN:0008-543X
1097-0142
DOI:10.1002/cncr.32645